Skip to content

Clinical trials

Phase 2 Metabolic Syndrome trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Metabolic Syndrome Phase: Phase 2 Clear all

107 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20013
20033
20047
20056
20066
20076
20088
20094
20104
20114
20123
20136
20148
20156
20161
20171
20184
20193
20202
20213
20222
20233
20244
20254
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed76
Terminated10
Recruiting7
Unknown status6
Withdrawn5
Not yet recruiting2
Active, not recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
University of Guadalajara7
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)4
University of Pennsylvania4
University of California, San Francisco3
Emory University2
Florida State University2
Gladwin, Mark, MD2
Johns Hopkins University2
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.2
Liminal BioSciences Ltd.2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Metabolic Syndrome107
Insulin Resistance37
Obesity24
Diabetes Mellitus14
Diabetes Mellitus, Type 214
Hypertension14
Cardiovascular Diseases11
Glucose Intolerance9
Overweight8
Dyslipidemias7

Trials

Showing 51 to 75 of 107. Each trial links to its page on Pharma Observatory.

7 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.